Variable | All participants (n = 2255) | Group A Low EQoL-VAS (0–50) (n = 487) | Group B Intermediate EQoL-VAS (51–75) (n = 784) | Group C High EQoL-VAS (76–100) (n = 984) | p-value | post hoc |
---|---|---|---|---|---|---|
eGFR, ml/min/1.73 m2 | 54.2 (19.6) | 53.2 (19.7) | 54.1 (21.2) | 55.7 (18.4) | 0.005 | a vs. c |
< 60 | 1423 (63.1) | 336 (69.0) | 494 (63.0) | 593 (60.3) | 0.005 | a vs. b |
a vs. c | ||||||
b vs. c | ||||||
< 45 | 560 (24.8) | 137 (28.1) | 206 (26.3) | 217 (22.1) | 0.020 | a vs. c |
b vs. c | ||||||
< 30 | 141 (6.3) | 37 (7.6) | 55 (7.0) | 49 (5.0) | 0.082 |  |
Diabetes | 568 (25.2) | 137 (28.1) | 225 (28.7) | 206 (21) | <  0.001 | a vs. b |
a vs. c | ||||||
b vs. c | ||||||
Hypertension | 1732 (76.8) | 409 (84.0) | 625 (79.7) | 698 (70.9) | <  0.001 | a vs. b |
a vs. c b vs. c | ||||||
Stroke | 131 (5.8) | 44 (9.0) | 50 (6.4) | 37 (3.8) | <  0.001 | a vs. b |
a vs. c b vs. c | ||||||
Hip Fractures | 111 (4.9) | 36 (7.4) | 44 (5.6) | 31 (3.2) | 0.001 | a vs. b |
a vs. c b vs. c | ||||||
Chronic obstructive pulmonary disease (COPD) | 267 (11.8) | 76 (15.6) | 99 (12.6) | 92 (9.3) | 0.002 | a vs. b |
a vs. c | ||||||
b vs. c | ||||||
Osteoporosis | 688 (30.5) | 186 (38.2) | 252 (32.1) | 250 (25.4) | <  0.001 | a vs. b |
a vs. c | ||||||
b vs. c | ||||||
Parkinson’s disease | 45 (2.0) | 22 (4.5) | 11 (1.4) | 12 (1.2) | <  0.001 | a vs. b |
a vs. c | ||||||
Anemia | 477 (21.2) | 137 (28.1) | 156 (19.9) | 184 (18.7) | <  0.001 | a vs. b |
a vs. c | ||||||
Cumulative Illness Rating Score (CIRS) | 8.0 (6.0) | 9.0 (7.0) | 8.0 (7.0) | 7.0 (6.0) | <  0.001 | a vs. b |
a vs. c b vs. c | ||||||
Take ≥5 current medications | 1509 (66.9) | 389 (79.9) | 554 (70.7) | 566 (57.5) | <  0.001 | a vs. b |
a vs. c b vs. c | ||||||
Lower urinary tract symptoms (LUTS) | 653 (29.0) | 173 (35.5) | 257 (32.8) | 223 (22.7) | <  0.001 | a vs. b |
a vs. c | ||||||
b vs. c | ||||||
Hemoglobin (Hb) | 13.5 ± 1.9 | 13.1 ± 1.5 | 13.5 ± 1.4 | 13.7 ± 1.4 | <  0.001 | a vs. c |